Tobacco Plants as Psychedelic Drug Factories

Genetically modifying tobacco plants presents a potentially more sustainable way to produce psychedelic drugs, which are experiencing increased demand for both research and medical applications. Currently, these compounds are typically sourced from various plants, fungi, and animals.

Agroinfiltration: A Simpler Production Process

Researchers argue that utilizing plants for drug manufacturing would be a simpler and more environmentally friendly alternative to existing production methods. This would facilitate research into therapeutic uses and streamline the development of future medicines.

How the Process Works

The team employed a technique called agroinfiltration, using a bacterium to introduce genes from other organisms into the tobacco plants. This process enables the plants to produce specific proteins, but the genetic changes aren’t permanently integrated into the plant’s genome, resulting in a temporary effect.

Controlling Spread and Expanding Potential

While permanent genetic modifications are possible, researchers like Aharoni acknowledge the potential complications, particularly concerning recreational drug use. “It’s a little bit tricky if we have it inherited, and then people will ask for seeds,” says Aharoni. The technique isn’t limited to tobacco, with potential applications in tomato, potato, and corn plants.

Addressing Sustainability Concerns

Aharoni emphasizes the growing understanding and acceptance of psychedelic compounds’ medical benefits. However, harvesting these compounds from natural sources poses risks to vulnerable populations and ecosystems threatened by habitat loss and overexploitation.

Demonstrated Production Levels

Researchers have already demonstrated the capability of these modified tobacco plants, discovering they can produce approximately 400 nanograms of cocaine per milligram of dried leaf – roughly a 25th of the concentration found in coca plants.

Expert Perspectives on the Breakthrough

John Fray at the University of Nottingham, UK, notes that around 25% of prescription drugs originate wholly or partially from plants. He highlights the significant opportunities to establish “green factories” capable of cultivating new compounds in greenhouse environments.

“If you want to understand something, you’ve got to be able to build something, so showing that you can make it in tobacco plants is useful,” says Fray. “As a technical accomplishment, to show that you understand the pathways and can do it, I think it has value.”